from WT mice were stimulated with increasing concentrations of CRP (0.1-50 µg/mL) and monitored for α-granule secretion by measuring surface CD62P levels. Response curves are expressed as percentage of maximal Geo-mean values, are shown, and represent two independent experiments. Gray circle inset denotes chosen CRP concentration (10 µg/mL) throughout the article. (B) Cardiomyocytes, pretreated with releasates from vehicle-treated (control) WT platelets or CRP-peptide (10 µg/mL), were subjected to ischemic injury and analyzed for changes in cell viability, with nonischemic (oxygenated control) samples monitored at 0-and 240-minute time points. Data mean AE SD, n ¼ 3.
Fig. S2
Quantification of platelet dense granule marker, ATP, in fractionated platelet releasates and the effect of adenosine on cardiomyocyte viability during ischemia. (A) Washed platelets (2 Â 10 8 /mL) from WT mice were treated with vehicle (control) or 10 µg/mL CRP (stimulated) for 15 minutes at 37°C. The isolated releasate was left untreated (unfiltered) or fractionated using a 3-kDa MW cutoff with centrifugation at 14,000g for 20 minutes. The filtered (<3 kDa) and retained (>3 kDa) fractions were readjusted to their original volume and, together with unfiltered samples, analyzed for ATP luminescence using luciferin-luciferase (Chrono-log, United States) on a microplate reader (Tecan Infinite M200Pro, Switzerland). Post measurement, 1 nmol of ATP standard was added as a reference value for absolute quantification of ATP. Data are mean AE SD; n ¼ 3, TH Open
